secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001437749-23-018677
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics authorizes $10M stock repurchase program through Dec 31, 2023
--------------------------------------------------------------------------------

- Board approved repurchase of up to $10M of common stock through December 31, 2023.
- Program is less than 10% of total cash as of March 31, 2023; cash runway exceeds three years.
- Repurchases may occur in open market or private transactions; no obligation to buy any shares.
- CEO states confidence in strategic priorities; CFO cites attractive valuation opportunity.
- Program may be suspended, modified, or terminated at any time without prior notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923018677/0001437749-23-018677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923018677/atos20230627_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-018677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer